{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:15:38Z","timestamp":1790511338152,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["P30AG062421"],"award-info":[{"award-number":["P30AG062421"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plasma-based biomarkers present a promising approach in the research and clinical practice of Alzheimer's disease as they are inexpensive, accessible and minimally invasive. In particular, prognostic biomarkers of cognitive decline may aid in planning and management of clinical care. Although recent studies have demonstrated the prognostic utility of plasma biomarkers of Alzheimer pathology or neurodegeneration, such as pTau-181 and NF-L, whether other plasma biomarkers can further improve prediction of cognitive decline is undetermined. We conducted an observational cohort study to determine the prognostic utility of plasma biomarkers in predicting progression to dementia for individuals presenting with mild cognitive impairment due to probable Alzheimer's disease. We used the Olink\u2122 Proximity Extension Assay technology to measure the level of 460 circulating proteins in banked plasma samples of all participants. We used a discovery data set comprised 60 individuals with mild cognitive impairment (30 progressors and 30 stable) and a validation data set consisting of 21 stable and 21 progressors. We developed a machine learning model to distinguish progressors from stable and used 44 proteins with significantly different plasma levels in progressors versus stable along with age, sex, education and baseline cognition as candidate features. A model with age, education, APOE genotype, baseline cognition, plasma pTau-181 and 12 plasma Olink protein biomarker levels was able to distinguish progressors from stable with 86.7% accuracy (mean area under the curve\u2009=\u20090.88). In the validation data set, the model accuracy was 78.6%. The Olink proteins selected by the model included those associated with vascular injury and neuroinflammation (e.g. IL-8, IL-17A, TIMP-4, MMP7). In addition, to compare these prognostic biomarkers to those that are altered in Alzheimer's disease or other types of dementia relative to controls, we analyzed samples from 20 individuals with Alzheimer, 30 with non-Alzheimer dementias and 34 with normal cognition. The proteins NF-L and PTP-1B were significantly higher in both Alzheimer and non-Alzheimer dementias compared with cognitively normal individuals. Interestingly, the prognostic markers of decline at the mild cognitive impairment stage did not overlap with those that differed between dementia and control cases. In summary, our findings suggest that plasma biomarkers of inflammation and vascular injury are associated with cognitive decline. Developing a plasma biomarker profile could aid in prognostic deliberations and identify individuals at higher risk of dementia in clinical practice.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac155","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:41:05Z","timestamp":1655214065000},"source":"Crossref","is-referenced-by-count":41,"title":["Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment"],"prefix":"10.1093","volume":"4","author":[{"given":"Pia","family":"Kivis\u00e4kk","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Magdamo","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca A","family":"Trombetta","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Noori","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi kai E","family":"Kuo","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori B","family":"Chibnik","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-3217","authenticated-orcid":false,"given":"Becky C","family":"Carlyle","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0899-7530","authenticated-orcid":false,"given":"Alberto","family":"Serrano-Pozo","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens R","family":"Scherzer","sequence":"additional","affiliation":[{"name":"Center for Advanced Parkinson Research and Precision Neurology Program, Harvard Medical School, Brigham and Women\u2019s Hospital , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T","family":"Hyman","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-6811","authenticated-orcid":false,"given":"Sudeshna","family":"Das","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Arnold","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Clinical & Translational Research Unit and Massachusetts Alzheimer\u2019s Disease Research Center, Department of Neurology, Harvard Medical School, Massachusetts General Hospital , Charlestown, MA 02129 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"2022082914182986300_fcac155-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"2022082914182986300_fcac155-B2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1212\/WNL.0000000000000055","article-title":"Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal","volume":"82","author":"Roberts","year":"2014","journal-title":"Neurology."},{"key":"2022082914182986300_fcac155-B3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp-2014-310095","article-title":"Risk factors for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease: A systematic review and meta-analysis of cohort studies","volume":"87","author":"Li","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2022082914182986300_fcac155-B4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease\u2014preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol Psychiatry."},{"key":"2022082914182986300_fcac155-B5","article-title":"Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia","author":"de Wolf"},{"key":"2022082914182986300_fcac155-B6","first-page":"1220","article-title":"a population-based cohort study","volume":"143","year":"2020","journal-title":"Brain."},{"key":"2022082914182986300_fcac155-B7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol."},{"key":"2022082914182986300_fcac155-B8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/ana.25885","article-title":"Plasma nt1 Tau is a specific and early marker of Alzheimer\u2019s disease","volume":"88","author":"Mengel","year":"2020","journal-title":"Ann Neurol."},{"key":"2022082914182986300_fcac155-B9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."},{"key":"2022082914182986300_fcac155-B10","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat Commun."},{"key":"2022082914182986300_fcac155-B11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nat Aging."},{"key":"2022082914182986300_fcac155-B12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","article-title":"A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease","volume":"94","author":"Sugarman","year":"2020","journal-title":"Neurobiol Aging."},{"key":"2022082914182986300_fcac155-B13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total Tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol."},{"key":"2022082914182986300_fcac155-B14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fneur.2015.00236","article-title":"Blood-based proteomic biomarkers of Alzheimer\u2019s disease pathology","volume":"6","author":"Baird","year":"2015","journal-title":"Front Neurol."},{"key":"2022082914182986300_fcac155-B15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/JAD-132102","article-title":"Prognostic polypeptide blood plasma biomarkers of Alzheimer\u2019s disease progression","volume":"40","author":"Yang","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"2022082914182986300_fcac155-B16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med."},{"key":"2022082914182986300_fcac155-B17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","article-title":"Plasma proteins predict conversion to dementia from prodromal disease","volume":"10","author":"Hye","year":"2014","journal-title":"Alzheimers Dement."},{"key":"2022082914182986300_fcac155-B18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neurobiolaging.2009.03.011","article-title":"Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"32","author":"Marksteiner","year":"2011","journal-title":"Neurobiol Aging."},{"key":"2022082914182986300_fcac155-B19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","article-title":"Identifying early markers of Alzheimer\u2019s disease using quantitative multiplex proteomic immunoassay panels","volume":"1180","author":"Soares","year":"2009","journal-title":"Ann N Y Acad Sci."},{"key":"2022082914182986300_fcac155-B20","doi-asserted-by":"crossref","first-page":"e29868","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer\u2019s disease","volume":"7","author":"Bjorkqvist","year":"2012","journal-title":"PLoS One."},{"key":"2022082914182986300_fcac155-B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WAD.0b013e31826d597a","article-title":"Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease","volume":"27","author":"Llano","year":"2013","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"2022082914182986300_fcac155-B22","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One."},{"key":"2022082914182986300_fcac155-B23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WAD.0000000000000279","article-title":"Version 3 of the National Alzheimer\u2019s coordinating center\u2019s uniform data set","volume":"32","author":"Besser","year":"2018","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"2022082914182986300_fcac155-B24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(13)70155-8","article-title":"The Harvard biomarker study\u2019s big plan","volume":"12","author":"Mohammadi","year":"2013","journal-title":"Lancet Neurol."},{"key":"2022082914182986300_fcac155-B25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"Pt 9","key":"2022082914182986300_fcac155-B26","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain."},{"key":"2022082914182986300_fcac155-B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"2022082914182986300_fcac155-B28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord."},{"key":"2022082914182986300_fcac155-B29","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2022082914182986300_fcac155-B30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1467-9868.2011.01004.x","article-title":"Strong rules for discarding predictors in lasso-type problems","volume":"74","author":"Tibshirani","year":"2012","journal-title":"J R Stat Soc Series B Stat Methodol."},{"key":"2022082914182986300_fcac155-B31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res."},{"key":"2022082914182986300_fcac155-B32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol."},{"key":"2022082914182986300_fcac155-B33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"2022082914182986300_fcac155-B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnagi.2017.00007","article-title":"Protein Tyrosine Phosphatase 1B (PTP1B): A potential target for Alzheimer\u2019s therapy?","volume":"9","author":"Vieira","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"2022082914182986300_fcac155-B35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 Leads to blood","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature."},{"key":"2022082914182986300_fcac155-B36","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1073\/pnas.1710329115","article-title":"Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer\u2019s disease","volume":"115","author":"Bennett","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2022082914182986300_fcac155-B37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 Leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature."},{"key":"2022082914182986300_fcac155-B38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","article-title":"Peripheral and central immune system crosstalk in Alzheimer disease \u2014 a research prospectus","volume":"17","author":"Bettcher","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"2022082914182986300_fcac155-B39","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/ncomms11934","article-title":"Early role of vascular dysregulation on late-onset Alzheimer\u2019s disease based on multifactorial data-driven analysis","volume":"7","author":"Iturria-Medina","year":"2016","journal-title":"Nat Commun."},{"key":"2022082914182986300_fcac155-B40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41593-021-00999-y","article-title":"Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level","volume":"25","author":"Johnson","year":"2022","journal-title":"Nat Neurosci."},{"key":"2022082914182986300_fcac155-B41","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)."},{"key":"2022082914182986300_fcac155-B42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial","volume":"321","author":"SPRINT MIND Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA."},{"key":"2022082914182986300_fcac155-B43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/alz.12123","article-title":"World-wide FINGERS network: A global approach to risk reduction and prevention of dementia","volume":"16","author":"Kivipelto","year":"2020","journal-title":"Alzheimers Dement."},{"key":"2022082914182986300_fcac155-B44","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.","volume":"12(1)","author":"Cullen","year":"2021","journal-title":"Nat Commun."},{"key":"2022082914182986300_fcac155-B45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnagi.2019.00220","article-title":"Deep learning in Alzheimer\u2019s disease: Diagnostic classification and prognostic prediction using neuroimaging data","volume":"11","author":"Jo","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"2022082914182986300_fcac155-B46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JAD-130842","article-title":"Predicting progression to dementia in elderly subjects with mild cognitive impairment using both cognitive and neuroimaging predictors","volume":"38","author":"Peters","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"2022082914182986300_fcac155-B47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-122440","article-title":"A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia","volume":"36","author":"Eckerstrom","year":"2013","journal-title":"J Alzheimers Dis."},{"key":"2022082914182986300_fcac155-B48","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/s41598-018-37769-z","article-title":"Predicting Alzheimer\u2019s disease progression using multi-modal deep learning approach","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep."}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac155\/44062450\/fcac155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/4\/fcac155\/45028282\/fcac155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/4\/fcac155\/45028282\/fcac155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T23:34:58Z","timestamp":1700696098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac155\/6608340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac155","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,14]]},"article-number":"fcac155"}}